Shishir K. Maithel, MD, FACS, FSSO ...

Dr. Shishir K. Maithel

Claim this profile

Emory University Hospital/Winship Cancer Institute

Studies Pancreatic Cancer
Studies Pancreatic Disease
5 reported clinical trials
17 drugs studied

Area of expertise

1

Pancreatic Cancer

Shishir K. Maithel has run 2 trials for Pancreatic Cancer. Some of their research focus areas include:

BRCA1 positive
BRCA2 positive
PALB2 positive
2

Pancreatic Disease

Shishir K. Maithel has run 1 trial for Pancreatic Disease.

Affiliated Hospitals

Image of trial facility.

Emory University Hospital/Winship Cancer Institute

Image of trial facility.

Emory University Hospital Midtown

Clinical Trials Shishir K. Maithel is currently running

Image of trial facility.

Olaparib

for Pancreatic Cancer

This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy.

Recruiting

0 awards

Phase 2

32 criteria

Image of trial facility.

Pump Chemotherapy

for Colorectal Cancer

This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the liver (liver metastases) and cannot be removed by surgery (unresectable). HAI uses a catheter to carry a tumor-killing chemotherapy drug called floxuridine directly into the liver. HAI is already approved by the Food and Drug Administration (FDA) for use in metastatic colorectal cancer to the liver, but it is only available at a small number of hospitals, and most of the time it is not used until standard chemotherapy stops working. Standard chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding HAI to standard chemotherapy may be effective in shrinking or stabilizing unresectable colorectal liver metastases.

Recruiting

2 awards

Phase 3

7 criteria

More about Shishir K. Maithel

Clinical Trial Related

2 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Shishir K. Maithel has experience with

  • Cefoxitin
  • Piperacillin-tazobactam
  • Cisplatin
  • Gemcitabine Hydrochloride
  • Lymphadenectomy
  • Partial Hepatectomy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Shishir K. Maithel specialize in?

Is Shishir K. Maithel currently recruiting for clinical trials?

Are there any treatments that Shishir K. Maithel has studied deeply?

What is the best way to schedule an appointment with Shishir K. Maithel?

What is the office address of Shishir K. Maithel?

Is there any support for travel costs?